A Phase 2, Randomized, Multiple-dose, Double-blind, Placebo-controlled Study of JKB-122 to Assess Liver Tests (ALT and AST) in HCV-positive Subjects Who Have Been Nonresponsive to Prior Interferon Based Therapies (Pegylated or Standard) Either Alone or in Combination With Ribavirin

Trial Profile

A Phase 2, Randomized, Multiple-dose, Double-blind, Placebo-controlled Study of JKB-122 to Assess Liver Tests (ALT and AST) in HCV-positive Subjects Who Have Been Nonresponsive to Prior Interferon Based Therapies (Pegylated or Standard) Either Alone or in Combination With Ribavirin

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs JKB 122 (Primary)
  • Indications Hepatitis C
  • Focus Pharmacodynamics
  • Sponsors Jenken Biosciences; TaiwanJ Pharmaceuticals
  • Most Recent Events

    • 03 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 May 2017.
    • 03 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 May 2017.
    • 03 Feb 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top